Semax is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-07. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
== Biosynthesis == Little gastrin I is synthesized from a 101-amino acid precursor protein called preprogastrin. A signal peptide of 21 amino acids is removed in the Endoplasmic reticulum, producing the 80-amino acid intermediate progastrin. Progastrin is then cleaved at specific site by Proprotein convertase as it moves through the Golgi apparatus toward secretory vesicles, producing gastrin-34 and gastrin-17 as the two major biologically active end products. In the normal human stomach, around 85% of amidated gastrin in the antral mucosa is in the G-17 form.
=== The Activation of Photo-Methionine === Because the previous synthesis had worked, photo-methionine is photo-reactive due to the diazirine ring. Once this ring has become exposed to UV light, nitrogen leaves as nitrogen gas (N2) and forms the highly reactive intermediate carbene. Photo-activation of amino acids provide the ability of photo-cross-linking in proteins. This type of cross-linking has three major advantages; there is greater specificity for this cross linking due to the short lived intermediates and that this amino acid is functional, and most importantly; not toxic (meaning it should not disrupt the protein's function or structure dramatically). Research had found that this activation is the rate-limiting step; not the cross-linkage.
Because genome-wide data still separate the lineages, they remain distinct species even though their history cannot be depicted by a simple bifurcating tree. Keuler and colleagues recommend routine hybridisation tests (e.g., gene-tree comparison, HybridDetective) in intensive delimitation projects. Overall, such studies highlight how cryptic and dynamic lichen species can be, and they continue to drive up recognized species numbers.
Argon is a chemical element; it has symbol Ar and atomic number 18. It is in group 18 of the periodic table and is a noble gas. Argon is the third most abundant gas in Earth's atmosphere, at 0.934% (9340 ppmv). It is more than twice as abundant as water vapor (which averages about 4000 ppmv, but varies greatly), 23 times as abundant as carbon dioxide (400 ppmv), and more than 500 times as abundant as neon (18 ppmv). Argon is the most abundant noble gas in Earth's crust, comprising 0.00015% of the crust. Nearly all argon in Earth's atmosphere is radiogenic argon-40, derived from the decay of potassium-40 in Earth's crust. In the universe, argon-36 is by far the most common argon isotope, as it is the most easily produced by stellar nucleosynthesis in supernovas. The name "argon" is derived from the Ancient Greek word ἀργόν, neuter singular form of ἀργός meaning 'lazy' or 'inactive', as a reference to the fact that the element undergoes almost no chemical reactions. The complete octet (eight electrons) in the outer atomic shell makes argon stable and resistant to bonding with other elements. Its triple point temperature of 83.8058 K is a defining fixed point in the International Temperature Scale of 1990. Argon is extracted industrially by the fractional distillation of liquid air. It is mostly used as an inert shielding gas in welding and other high-temperature industrial processes where ordinarily unreactive substances become reactive; for example, an argon atmosphere is used in graphite electric furnaces to prevent the graphite from burning.
He looked pale, delicate and shaky, not his usual robust self: "He was very ill when he got here." After being taken by Reitell to check in at the Chelsea Hotel, Thomas took the first rehearsal of Under Milk Wood. They then went to the White Horse Tavern in Greenwich Village, before returning to the Chelsea Hotel. The next day, Reitell invited him to her apartment, but he declined. They went sightseeing, but Thomas felt unwell and retired to his bed for the rest of the afternoon. Reitell gave him half a grain (32.4 milligrams) of phenobarbitone to help him sleep and spent the night at the hotel with him. Two days later, on 23 October, at the third rehearsal, Thomas said he was too ill to take part, but he struggled on, shivering and burning with fever, before collapsing on the stage. The following day, 24 October, Reitell took Thomas to see her doctor, Milton Feltenstein, who administered cortisone injections and Thomas made it through the first performance that evening, but collapsed immediately afterwards. "This circus out there," he told a friend who had come back-stage, "has taken the life out of me for now." Reitell later said that Feltenstein was "rather a wild doctor who thought injections would cure anything."
Sources: en.wikipedia.org
=== HIV/AIDS-associated diarrhea === In a randomized controlled trial involving patients with advanced HIV/AIDS, S. boulardii supplementation was associated with a higher recovery rate from chronic diarrhea compared with placebo. Participants receiving S. boulardii also experienced weight gain, whereas those in the placebo group lost weight over the 18-month study period. No adverse reactions were reported in this immunocompromised population
The arachnoid layer was first described by Dutch physician Gerardus Blasius in 1664. In 1695, Humphrey Ridley first described the subarachnoid cisterns. He also contributed to the understanding of the blood-brain barrier, and accurately described the fifth cranial nerve ganglion with its branches. In 1699, Frederick Ruysch confirmed that the arachnoid mater formed a complete layer that surrounded the brain. Its current name is based on his description of its spiderlike morphology. Arachnoid granulations were first described by Italian physician Antonio Pacchioni who published his Dissertatio Epistolaris de Glandulis Conglobatis Durae Meningis Humanae in 1705. In seven articles from 1899 to 1902, Italian anatomist Giuseppe Sterzi described comparative studies on the meninges from the lancelet to the human. He showed that the spinal meninges were very simple in adult lower vertebrates and in the early development of more advanced vertebrates.
RNH2 + [CH3SC(NH2)2]+X− → [RN(H)C(NH2)2]+X− + CH3SH The resulting guanidinium ions can often be deprotonated to give the guanidine. This approach is sometimes called the Rathke synthesis, in honor of its discoverer Bernhard Rathke.
=== Infectious diseases === Among the human-specific infectious pathogens studied on humanized mice models, the human immunodeficiency virus has been successfully studied. Besides this, humanized models for studying Ebola virus, Hepatitis B, Hepatitis C, Kaposi's sarcoma-associated herpesvirus, Leishmania major, malaria, and tuberculosis have been reported by various studies. NOD/scid mice models for dengue virus and varicella-zoster virus, and a Rag2null𝛾cnull model for studying influenza virus have also been developed.
She has also been involved in creating a new zebrafish model to study the role of glutathione S-transferase π1 in development, redox homeostasis, and drug response involving cytotoxicity through endoplasmic reticulum stress and unfolded protein response. Additionally, in an Antioxidants & Redox Signaling review, she analyzed the influence of the S-glutathionylation cycle on protein structure, cellular regulation, and its significance for interventions in stress- and aging-related pathologies. Furthermore, her research has demonstrated that altered GSTP expression within the endoplasmic reticulum regulates protein homeostasis (proteostasis) through S-glutathionylation of ER resident proteins, including PDI and BiP. GSTP leads to S-glutathionylation of binding immunoglobulin protein (BiP), contributing to acquired resistance to Btz in multiple myeloma (MM) cells, representing a novel mechanism of drug resistance in MM. She has also emphasized GSTπ's novel role in enhancing S-glutathionylation reactions under oxidative and nitrosative stress, with implications for stress response and drug resistance in tumors.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.